More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.
New WHO Collaborating Centre hosted by RIVM on Life Course and Health The World Health Organization (WHO) has designated RIVM as WHO Collaborating Centre on Life Course and Health. The Collaborating Centre will support the WHO by contributing to knowledge and research on healthy ageing over the life course. People are growing older all over the world.
Safety of materials and products already starts at the design phase The Ministry of Infrastructure and Water Management aims to ensure that all new materials and technological developments are safe in 2050.
Air quality Sint Maarten landfill At the beginning of 2019, RIVM measured the air quality around the landfill at Philipsburg, Sint Maarten for two weeks. No or hardly any harmful substances were measured.
RIVM will make measurements around the Sint Maarten landfill From 21 January 2019, a team from RIVM will travel to Sint Maarten to make measurements and take samples at various locations around the landfill in Philipsburg.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
Health effects due to titanium nanoparticles in food and toothpaste cannot be excluded Health effects due to exposure to titanium dioxide nanoparticles via food, food supplements and toothpaste cannot be excluded.
Tool for risk assessment of nanomaterials in cosmetics Both regulators and manufacturers need to evaluate and manage consumer health risks that may be posed by the use of nanomaterials in cosmetics.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.